公司概覽
業務類別 Biotechnology
業務概覽 Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
公司地址 100 Fifth Avenue, Waltham, MA, USA, 02451
電話號碼 +1 617 977-5700
傳真號碼 --
公司網頁 https://www.apellis.com
員工數量 739
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. David Acheson Executive Vice President, Commercial -- 13/01/2025
Mr. Timothy E. Sullivan Chief Financial Officer and Treasurer 美元 530.96K 24/02/2026
Dr. Cedric Francois, M.D. Director, Chief Executive Officer and President 美元 793.19K 24/02/2026
Mr. Pascal Deschatelets, PhD Chief Scientific Officer -- 23/04/2025
Mr. David Watson General Counsel and Secretary 美元 513.08K 23/04/2025
Ms. Nur Nicholson Chief Technical Operations Officer -- 23/04/2025
Mr. James George Chopas Vice President, Corporate Controller, Treasurer and Chief Accounting Officer -- 24/02/2026
Dr. Caroline Baumal, M.D. Chief Medical Officer 美元 610.39K 23/04/2025
Mr. Mark Jeffrey DeLong Chief Business and Strategy Officer -- 23/04/2025
 
董事會成員
董事會 職務 更新日期
Ms. Keli Walbert Independent Director 24/02/2026
Mr. Alec Machiels Independent Director 24/02/2026
Dr. Gerald L. Chan, Sc.D. Chairman of the Board 24/02/2026
Ms. Stephanie Monaghan O’Brien Independent Director 24/02/2026
Dr. Cedric Francois, M.D. Director, Chief Executive Officer and President 24/02/2026
Mr. A. Sinclair Dunlop Independent Director 24/02/2026
Mr. Paul Fonteyne, M.S. Independent Director 24/02/2026
Dr. G. Mikael Dolsten, M.D.,PhD Independent Director 02/03/2026
Mr. Craig A. Wheeler Independent Director 24/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:34)
代號 名稱 佔比% 持有日期
FYXFirst Trust Small Cap Core AlphaDEX® ETF0.06%26/02/2026
SCHBSchwab US Broad Market ETF™0.05%28/02/2026
IYHiShares US Healthcare ETF0.05%28/02/2026
FHLCFidelity MSCI Health Care ETF0.03%28/02/2026
ONEQFidelity Nasdaq Composite ETF0.03%27/02/2026
SMMDiShares Russell 2500 ETF0.03%28/02/2026
BBPVirtus LifeSci Biotech Products ETF0.02%27/02/2026
BBSCJPMorgan BetaBuilders US Sml Cp Eq ETF0.02%27/02/2026
IWViShares Russell 3000 ETF0.02%28/02/2026
EQALInvesco Russell 1000 Equal Weight ETF0.02%27/02/2026
ISCGiShares Morningstar Small-Cap Growth ETF0.02%28/02/2026
RZGInvesco S&P SmallCap 600® Pure Gr ETF0.02%27/02/2026
EESWisdomTree US SmallCap Earnings ETF0.02%27/02/2026
ESGVVanguard ESG US Stock ETF0.02%31/01/2026
SPTMState StreetSPDRPortS&P1500CompStkMktETF0.02%27/02/2026
DFACDimensional US Core Equity 2 ETF0.02%27/02/2026
SMLFiShares U.S. Small-Cap Eq Fac ETF0.01%28/02/2026
VONEVanguard Russell 1000 ETF0.01%31/01/2026
FADFirst Trust Multi Cap Gr AlphaDEX® ETF0.01%26/02/2026
DFUSDimensional US Equity Market ETF0.01%27/02/2026
  1   2    3    4    5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.